Adaptively evolved human oral actinomyces‐sourced defensins show therapeutic potential

The development of eukaryote‐derived antimicrobial peptides as systemically administered drugs has proven a challenging task. Here, we report the first human oral actinomyces‐sourced defensin—actinomycesin—that shows promise for systemic therapy. Actinomycesin and its homologs are only present in ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Shunyi, Gao, Bin, Umetsu, Yoshitaka, Peigneur, Steve, Li, Ping, Ohki, Shinya, Tytgat, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819291/
https://www.ncbi.nlm.nih.gov/pubmed/34927385
http://dx.doi.org/10.15252/emmm.202114499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819291/
https://www.ncbi.nlm.nih.gov/pubmed/34927385
http://dx.doi.org/10.15252/emmm.202114499

Ejemplares similares